Tag Archives: POC

Discovery of LX2931 (Sphingosine 1-Phosphate Lyase Inhibitor) & Phase IIa Data


Fingolimod (FTY720, Gilenya), an immunosuppresive agent with activity purported to be mediated by binding of it’s phosphorylated derivative to the sphingosine-1-phosphate receptor 1 (S1P1), was approved earlier in the year as the first orally administered disease modifying therapy for the treatment … Continue reading

Posted in Clinical Candidates, Enzyme Inhibitors | Tagged , , , , , , , , , , , , , , , | Leave a comment

Discovery of PF-04457845 (FAAH Inhibitor)


In this latest publication from the Pfizer labs, the authors describe their continuing efforts to identify urea-based, irreversible inhibitors of fatty acid amide hydrolase (FAAH).  Inhibition of FAAH and the concomitant elevation of endogenous levels of fatty acid amides has … Continue reading

Posted in Clinical Candidates, Enzyme Inhibitors | Tagged , , , , , , , , , , , | Leave a comment

The Discovery of RG1678 (Gly-T1 inhibitor)


In this interesting J.Med.Chem. article workers from Roche describe the optimisation of a series of benzoylpiperazines as Gly-T1 inhibitors for the treatment of schizophrenia culminating in the discovery of RG1678, the first potent and selective Gly-T1 inhibitor to demonstrate efficacy … Continue reading

Posted in Clinical Candidates, Transporter Modulator | Tagged , , , , , , , , , | Leave a comment